Last ¥2,357 JPY
Change Today -73.00 / -3.00%
Volume 801.0K
As of 1:00 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

kaken pharmaceutical co ltd (4521) Snapshot

Open
¥2,450
Previous Close
¥2,430
Day High
¥2,452
Day Low
¥2,345
52 Week High
11/4/14 - ¥2,820
52 Week Low
03/17/14 - ¥1,479
Market Cap
228.3B
Average Volume 10 Days
351.7K
EPS TTM
¥127.92
Shares Outstanding
96.9M
EX-Date
03/27/15
P/E TM
18.4x
Dividend
¥54.00
Dividend Yield
2.16%
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its pharmaceutical and medical devices products include Artz, an anti-osteoarthritis drug for use in treating knee joint pain accompanied by chronic rheumatoid arthritis; Procylin, which is used to treat chronic artery occlusive diseases and pulmonary hypertension; Adofeed, a pain and inflammation-relieving plaster; Mentax for the treatment of superficial mycosis; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing product. The company’s pharmaceutical and medical devices products also comprise Ebrantil, a a1 blocker to treat dysuria and hypertension; Berasus for use in treating pulmonary arterial hypertension; Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery under; and Seprafilm, an anti-adhesive absorbent barrier. Its agrochemicals consist of Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. The company’s animal health products include Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Its products under development include KCB-1D, a Phase-III clinical trial product for the treatment of periodontitis; KAG-308, which is in Phase-I clinical trial for the treatment of Ulcerative colitis; and SI-657 that is in Phase-III clinical trials for the treatment of Enthesopathy. The company also owns and rents bunkyo green court commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

1,540 Employees
Last Reported Date: 06/27/14
Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kaken pharmaceutical co ltd (4521) Key Developments

Kaken Pharmaceutical Co. Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2014; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2015

Kaken Pharmaceutical Co. Ltd. announced consolidated earnings results for the six months ended September 30, 2014. For the period, the company reported net sales of JPY 44,232 million against JPY 43,712 million a year ago. Operating income was JPY 8,806 million against JPY 7,358 million a year ago. Ordinary income was JPY 8,677 million against JPY 7,211 million a year ago. Net income was JPY 5,639 million against JPY 4,598 million a year ago. Basic net income per share was JPY 67.28 against JPY 53.57 a year ago. Income before income taxes and minority interests was JPY 8,654 million against JPY 7,187 million a year ago. Net cash provided by operating activities was JPY 3,175 million against JPY 6,252 million a year ago. Purchase of property, plant and equipment was JPY 749 million against JPY 1,111 million a year ago. Purchase of intangible assets was JPY 47 million against JPY 29 million a year ago. The company provided consolidated earnings guidance for the year ending March 31, 2015. For the year, the company expects net sales of JPY 91,400 million, operating income of JPY 16,800 million, ordinary income of JPY 16,400 million, net income of JPY 10,700 million and basic net income per share of JPY 129.10.

Kaken Pharmaceutical Co. Ltd. to Report Q2, 2015 Results on Nov 06, 2014

Kaken Pharmaceutical Co. Ltd. announced that they will report Q2, 2015 results on Nov 06, 2014

Kaken Pharmaceutical Co. Ltd., Q2 2015 Earnings Call, Nov 07, 2014

Kaken Pharmaceutical Co. Ltd., Q2 2015 Earnings Call, Nov 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4521:JP ¥2,357.00 JPY -73.00

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies
 

Industry Analysis

4521

Industry Average

Valuation 4521 Industry Range
Price/Earnings 16.9x
Price/Sales 2.0x
Price/Book 2.6x
Price/Cash Flow 19.0x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAKEN PHARMACEUTICAL CO LTD, please visit www.kaken.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.